In today's edition: tobacco, tariffs and Ebola
In today's edition: food safety omnibus, EU-US trade, Agri-AI
Also, in Thursday’s edition: Metsola third term, Bas Eickhout, Taliban, Oil ban, Jozef Síkela
Only around half of European countries offer sex education in schools
Vsora backs EU push for fabless chips and sovereign cloud
Consumer groups' complaint records nearly 900 financial scam ads suspected of breaching DSA
European Commission faces growing pressure after dropping it from agenda without explanation
Friedrich Merz is pushing for Ukraine to be inside inside the EU without 'further delays'
The republic is home to 5 million people and 7 million methane-making cows
The EU’s long-awaited Arctic strategy will be finalised this autumn, Síkela tells Euractiv
European governments face pressure to act against Iranian military attachés accused of operating under diplomatic cover
Ukraine's expertise doesn't stop at drones, Alyona Getmanchuk told Euractiv
As the war in Iran drags on, leaders at the Pentagon have increasingly moved to avoid disclosing key information that runs counter to the White House's narrative. The Department of Defense has moved to classify information related to Iran, as [...]
One of the most sensitive units engaged in French electronic warfare is set to change its director this summer. Intelligence [...]
Ukrainian Prosecutor General Ruslan Kravchenko is working with the NGO LingvaLexa to prepare cases to be brought before international courts [...]
Chinese interference in the world's seven leading democracies is "systemic", according to a report by Montreal Institute for Global Security [...]
Relations between the French Minister for the Armed Forces, Catherine Vautrin, and her deputy minister, Alice Rufo, are frosty, according [...]
War, empire, and the forgotten power of the United Nations.
New report says accelerated approval pathway for early-phase clinical trials could save Poland’s health system millions while attracting high-value biomedical investment
Benoît van den Hove tells Euractiv that scaling biotech companies at a global level still depends on capital that Europe does not yet mobilise at sufficient scale
Pages